AQR Capital Management
MACK

AQR Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

AQR Capital Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-10,536
Closed -$705K – 2355
2015
Q3 		$705K Sell
10,536
-3,971
-27% -$324K ﹤0.01% 1598
2015
Q2 		$1.41M Buy
14,507
+2,064
+17% +$196K ﹤0.01% 1344
2015
Q1 		$1.16M Sell
12,443
-686
-5% -$58.4K ﹤0.01% 1347
2014
Q4 		$1.17M Buy
13,129
+432
+3% +$31.5K ﹤0.01% 1576
2014
Q3 		$877K Buy
+12,697
New +$678K ﹤0.01% 1681

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

AQR Capital Management's MACK Position: Q4 2015 in Review

AQR Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2015, closing a stake of 10,536 shares — an estimated $705K sold.

AQR Capital Management first reported a position in MACK in Q3 2014 and held it in 5 quarters. The position peaked at $1.41M in Q2 2015. 139 funds tracked by Wall St. Rank hold MACK as of Q4 2015.

  • AQR Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • AQR Capital Management sold 10,536 Merrimack Pharmaceuticals, Inc. shares in Q4 2015, an estimated $705K.
  • AQR Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2014 and held it in 5 quarters.
  • AQR Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $1.41M in Q2 2015.
  • 139 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2015.

Based on AQR Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.